An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome
Completed · Phase 2
Conditions studied: Atypical Hemolytic-Uremic Syndrome
In brief
The record Primary purpose is to assess the efficacy of eculizumab in adult patients with Atypical Hemolytic- Uremic Syndrome (aHUS) to control Thrombotic Microangiopathy (TMA) as characterized by thrombocytopenia, hemolysis and renal impairment.
Key facts
- Study ID
- NCT01194973
- Run by
- Alexion Pharmaceuticals, Inc.
- People needed
- 44
- Starts
- 2010-07-01
- Expected to finish
- 2014-02-01
- Last updated by the study team
- 2017-05-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Study site — Burlington, Massachusetts, United States
- Study site — Hackensack, New Jersey, United States
- Study site — New York, New York, United States
- Study site — Columbus, Ohio, United States
- Study site — Houston, Texas, United States
- Study site — Liège, Belgium
- Study site — Caen, France
- Study site — Lille, France
- Study site — Nantes, France
- Study site — Nice, France
- Study site — Paris, France
- Study site — Paris, France
- Study site — Toulouse, France
- Study site — Tours, France
- Study site — Essen, Germany
- Study site — Hanover, Germany
- Study site — Bergamo, Italy
- Study site — Florence, Italy
- Study site — Barcelona, Spain
- Study site — Córdoba, Spain
- Study site — Exeter, United Kingdom
- Study site — London, United Kingdom
- Study site — Newcastle, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.